Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Louisiana Health Daily.
Press releases published on September 5, 2025
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, …
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société …
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock …
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to …
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to …
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting
Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 (GLOBE …
Streamlined Cancer Tissue Analysis at KFSHRC Improves Patient Journey
RIYADH, Saudi Arabia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre applies Large-Format Tissue Processing to support a smoother, more reassuring diagnostic experience for patients undergoing cancer surgery. The …
Healthinsurance.org: 5 ways to prepare now for Marketplace open enrollment
Minneapolis, MN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- With Marketplace enrollees facing new documentation requirements and potentially large premium increases, now is the time to prepare for enrolling in 2026 coverage. According to healthinsurance.org, …
WellSpan announces changes to further enhance the safety and security of its facilities
York, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) -- In support of its commitment to patient and team member safety, WellSpan Health today announced plans to further enhance security in its facilities, including increased weapons detection at entrances to its …
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage …
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod …
Safety Shot Appoints BONK Core Contributor Mitchell Rudy (Nom) to Board of Directors
Transition Marks Next Phase in Company’s Strategic Integration with the Digital Asset Ecosystem SCOTTSDALE, AZ, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT), a company evolving to bridge the gap between traditional public markets and …
Tiziana Life Sciences Announces Purchase of Shares by Chairman
BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …